C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 25.05 PLN 0.2% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Celon Pharma SA?
Write Note
Section:
 

Relative Value

The Relative Value of one CLN stock under the Base Case scenario is 17.77 PLN. Compared to the current market price of 25.05 PLN, Celon Pharma SA is Overvalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CLN Relative Value
Base Case
17.77 PLN
Overvaluation 29%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

6.1
P/S
P/S
Price to Sales
6.1
vs History
52
vs Industry
21
Median 3Y
4.1
Median 5Y
6.7
Industry
2.5
Forward
5.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-28.2
Median 5Y
-26.6
Industry
21.8
Forward
-63.5
More Details
225.8
P/OCF
P/OCF
Price to OCF
225.8
vs History
19
vs Industry
0
Median 3Y
28.5
Median 5Y
30.3
Industry
16.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-22
Median 5Y
-23
Industry
23.8
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
46
vs Industry
25
Median 3Y
1.8
Median 5Y
2.8
Industry
2.1
More Details
5.6
EV/S
EV/S
Enterprise Value to Sales
5.6
vs History
50
vs Industry
21
Median 3Y
3.3
Median 5Y
6
Industry
2.7
Forward
5
More Details
7.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.9
vs History
50
vs Industry
24
Median 3Y
5.1
Median 5Y
8.6
Industry
5.2
More Details
185.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
185.3
vs History
4
vs Industry
6
Median 3Y
41.5
Median 5Y
51.9
Industry
13.5
Forward
33.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-26.2
Median 5Y
-24
Industry
16.8
Forward
-79.6
More Details
205.8
EV/OCF
EV/OCF
Enterprise Value to OCF
205.8
vs History
19
vs Industry
0
Median 3Y
22.9
Median 5Y
28.1
Industry
15.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-22
Industry
19.3
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
47
vs Industry
27
Median 3Y
1.6
Median 5Y
2.7
Industry
1.9
More Details

Multiples Across Competitors

CLN Competitors Multiples
Celon Pharma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Celon Pharma SA
WSE:CLN
1.3B PLN 6.1 -28.1 185.3 -26.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
PL
C
Celon Pharma SA
WSE:CLN
Average P/S: 382 942.5
6.1
15%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
PL
C
Celon Pharma SA
WSE:CLN
Average P/E: 32.3
Negative Multiple: -28.1 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
C
Celon Pharma SA
WSE:CLN
Average EV/EBITDA: 432.1
185.3
136%
1.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
C
Celon Pharma SA
WSE:CLN
Average EV/EBIT: 2 011.2
Negative Multiple: -26.2 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Summary
CLN intrinsic value, competitors valuation, and company profile.
DCF Valuation
CLN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CLN stock valuation using valuation multiples.
Wall Street Estimates
CLN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CLN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.